Uganda Begins Phase 1 Trial of Ebola Vaccine for Bundibugyo Strain
Phase 1 trial of a vaccine candidate is underway in Masaka, southern Uganda
In Brief
- •Phase 1 trial of a vaccine candidate is underway in Masaka, southern Uganda
- •The vaccine targets the Bundibugyo strain of the Ebola virus, which is currently circulating in the region
- •No approved treatment or vaccine exists for the Bundibugyo strain
- •The trial commenced on 17 October 2026, as reported by France24
- •The study aims to assess safety and immunogenicity of the candidate vaccine
Why It Matters
The Bundibugyo strain of Ebola has caused sporadic outbreaks in Uganda, and the absence of an approved vaccine or treatment underscores the urgency of developing effective countermeasures. A successful Phase 1 trial would provide critical safety data and pave the way for larger efficacy studies, potentially safeguarding communities in the region and beyond from future outbreaks.
Key Details
- Trial Phase
- Phase 1
- Location
- Masaka, Uganda
- Target Strain
- Bundibugyo
- Approved Vaccine Availability
- None
Original Reporting & Sources
VNews is an independent briefing product. Original reporting remains credited to the following publishers:
This brief was synthesized automatically using attributed third-party reporting. VNews is a digital news publication produced under the VContent Group brand and operated by Francis Vincent Sunday in Ghana, independent from the publishers cited above. Read our AI Transparency Policy and Editorial & Corrections Policy.